GlassScriptPhysician profile
Matthew William Arnold
NPI 1477504926
$2,804.49
in general payments reported to CMS, 2019-2025
19 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $421 · 2021: $193 · 2022: $181 · 2023: $222 · 2024: $130 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $36.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.59 |
| Education | $36.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.08 | 2021-2025 | Duopa |
| Medtronic USA, INC. | $308.85 | 2019-2020 | |
| Acorda Therapeutics, INC | $269.05 | 2019-2023 | Inbrija |
| Lilly USA, LLC | $205.63 | 2019 | |
| Acadia Pharmaceuticals INC | $171.88 | 2020-2022 | |
| Mdd US Operations, LLC | $139.38 | 2025 | |
| Rapid Medical LTD | $137.62 | 2025 | Tigertriever 17 Revascularization Device, Comaneci 17 |
| Teva Pharmaceuticals USA, INC. | $129.89 | 2019 | |
| Sunovion Pharmaceuticals INC. | $124.81 | 2019 | |
| Kyowa Kirin, INC. | $124.02 | 2020 | |
| Abbott Laboratories | $115.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $112.46 | 2024 | Crexont |
| Allergan, INC. | $101.83 | 2020 | |
| Boston Scientific Corporation | $95.72 | 2019 | |
| Biogen, INC. | $93.93 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $70.34 | 2025 | |
| Neurocrine Biosciences, INC. | $70.30 | 2022 | |
| Ucb, INC. | $60.15 | 2019-2025 | Rystiggo |
| Alexion Pharmaceuticals, INC. | $31.55 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.